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S U M M A R Y
Background: Subclinical morbidity due to schistosomiasis was evaluated in 565 patients, and the
enhanced liver ﬁbrosis (ELF) test was assessed for the ﬁrst time as a potential screening tool for disease.
Methods: The prevalence and intensity of infection were determined by Kato–Katz thick smear stool
examination at baseline and 2 years after curative treatment. The degree of hepatic ﬁbrosis was assessed
by ultrasound. Non-invasive serum biomarkers of hepatic ﬁbrosis were also evaluated.
Results: The baseline human prevalence and infection intensitywere found to bemoderately high at 34%
and 123 eggs per gram, respectively. However, hepatic parenchymal ﬁbrosis occurred in 50% of subjects,
with grade II ﬁbrosis in 19% and grade III in 6%. The ELF score and higher serum levels of tissue inhibitor of
metalloproteinase 1 (TIMP-1) and hyaluronic acid (HA) correlated with the grade of liver ﬁbrosis.
Conclusions: The ﬁndings of this study demonstrated that praziquantel treatment had a short-term
impact on both the prevalence and intensity of infection, but less of an impact on established morbidity.
Higher TIMP-1 and HA serum levels, and an ELF cut-off score of 8 were found to be correlated with the
grade of liver ﬁbrosis; these values may, therefore, assist physicians in identifying individuals at greater
risk of disease.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Schistosomiasis is a major public health problem that afﬂicts
approximately 240 million people worldwide1 [9_TD$DIFF] and causes
approximately 70 million disability-adjusted life years lost.2
Preventive chemotherapy has been endorsed and advocated by
the World Health Organization (WHO) for the global control of
schistosomiasis.3 Since its inception in 1979, much optimism has
surrounded mass drug administration (MDA) for the worldwide
control of schistosomiasis, for which praziquantel (PZQ) has served
as the cornerstone drug. Numerous studies have claimed that
preventive chemotherapy (i.e., 40 mg/kg PZQ) given once or twice* Corresponding author.[23_TD$DIFF] Grifﬁth University, University Drive, Meadowbrook QLD
4131, Australia
http://dx.doi.org/10.1016/j.ijid.2016.10.024
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).yearly can signiﬁcantly reduce the prevalence and intensity of
infection and control morbidity in the long term.3
Schistosomiasis was ﬁrst reported in the Philippines in
1906. Approximately 865 000 people are currently infected and
a further 12 million are at risk of infection.3,4 Major endemic foci
(80%) are in the poorest regions of the Visayas (Samar and Leyte)
and Mindanao.3,4 The current national control program comprises
annual free MDA (40 mg/kg PZQ) in all schistosomiasis-endemic
communities with a prevalence of >10%. The Philippines National
Schistosomiasis Control Program has recently reported that the
human prevalence has declined to less than 3% nationally.5
However, contradictory reports claim the program is failing
because of poor drug compliance, poor drug coverage, infrequent
monitoring and evaluation, and rapid re-infection rates.4–6
Moreover, newly published data have revealed very high preva-
lence rates in both humans and bovines in endemic areasciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Figure 1. Study proﬁle and compliance among 18 221 residents from
22 schistosomiasis-endemic barangays in Palapag and Laoang, Northern Samar,
the Philippines. All inhabitants aged 5–65 years were invited to participate in the
questionnaire and provide two stool samples for parasitological examination. A
subset of patients (n = 736) were selected for ultrasound investigations.
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asis cases and disease-related deaths being reported by the
National Department of Health for Mindanao, Samar, Leyte, and
Oriental Mindoro.4
Hepatic ﬁbrosis is the major cause of morbidity and mortality
among people with chronic schistosomiasis. Schistosomiasis-
induced liver ﬁbrosis in the ﬁeld setting is best assessed with a
portable ultrasound.6 The instrument has been reliable for
detecting and assessing the degree of parasite-induced liver
abnormalities and for monitoring pathology regression following
anti-schistosome treatment.6 Despite inter-observer variability
related to its use,8 several studies have conﬁrmed its usefulness in
evaluating hepatosplenic schistosomiasis in the ﬁeld over the past
30 years.6,9–17 [24_TD$DIFF] The potential of non-invasive markers to comple-
ment the imaging assessment of organmorbidity has been studied
before.5 Among the most promising for assessing schistosome-
induced liver ﬁbrosis are hyaluronic acid (HA), collagenous
proteins, matrix metalloproteinases, and intercellular adhesion
molecules.5,14,15
In this study, the clinical morbidity due to schistosomiasis at
baseline and at 2 years after curative treatment was evaluated
among 565 residents of a known endemic area in Northern Samar,
the Philippines. Furthermore, the enhanced liver ﬁbrosis (ELF) test
was assessed as a potential ﬁeld screening tool for advanced
disease.
2. Methods
2.1. Study area
The study area comprised 18 schistosomiasis-endemic bar-
angays in the municipalities of Laoang and Palapag, Northern
Samar, the Philippines. Residents of this area are typically poor rice
farmers with family incomes far below the national average. Over
50% of the population lives below the poverty line, and the water
supply, sanitation, and hygiene are rudimentary.7 The area is non-
endemic for malaria but has had an active schistosomiasis control
program for more than over [26_TD$DIFF]three [27_TD$DIFF]decades, including an MDA
program that commenced in 2008. All individuals aged 5–65 years
are offered free annual treatment (40 mg/kg of PZQ) in accordance
with the Department of Health Administrative Order 2007–0015.7 [25_TD$DIFF]
2.2. Study procedures
A cross-sectional schistosomiasis survey involving approxi-
mately 20 000 individuals was conducted in 2012 in order to
determine the prevalence, intensity of infection, and morbidity
associated with the disease (Figure 1).7 The baseline prevalence
and intensity of infection were determined by Kato–Katz thick
smear stool examination. Individuals were asked, over the course
of a week, to provide two stool specimens from which six 50 g
Kato–Katz thick smears were prepared on microscope slides
according to establishedmethods.20 Slides were examined under a
light microscope by experienced laboratory technicians, who
counted the number of Schistosoma japonicum eggs per slide. For
quality control, 10% of all slides were randomly selected and re-
examined by a senior microscopist at the Research Institute for
Tropical Medicine, Manila. S. japonicum egg counts were expressed
as eggs per gram (epg) of stool.18 The intensity of infection was
graded according to WHO criteria: light infection, 1–99 epg;
moderate infection, 100–399 epg; heavy infection, 400 epg.19
For a more accurate assessment of schistosome-induced
hepatosplenic morbidity, ultrasonographic studies were per-
formed on a subset of individuals with symptoms and signs
suggestive of schistosomiasis. All subjects (n = 736) who reported
gastrointestinal and/or neurological symptoms (i.e., fatigue,malaise, abdominal pain, blood per rectum, hematemesis, diar-
rhea, jaundice, dizziness, headache, and seizures) and/or were
clinically assessed to havemorbidity (i.e., palpable liver and spleen,
varices, ascites, etc.) based on physical examination were initially
selected for the ultrasound investigation. However, only those
with baseline stool and ultrasound examination results were
included in the ﬁnal analysis (n = 565). The degree of hepatic
ﬁbrosis was assessed by ultrasound examination using a portable
gray-scale ultrasonogram equipped with 3 MHz curve array
transducer (SONOACE X1; Madison Co., Ltd, Seoul, South Korea).
Liver size was measured in millimeters along the mid-sternal line
(MSL) andmid-clavicular line (MCL) for the left lobe and right lobe,
respectively. Spleen size was measured in millimeters along the
left mid-axillary line (MAL). Hepatic ﬁbrosis grading was adopted
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the WHO/TDR in 2000 (WHO Special Programme for Research and
Training in Tropical Diseases).20 [28_TD$DIFF] Ultrasound ﬁndings were arrived
at by consensus agreement of two experienced ultrasonographers.
Ten percent of the ultrasound images were independently
validated by a radiologist in Manila.
Serum biomarkers of hepatic ﬁbrosis were also evaluated on a
random subset of patients. The selection of the sample subset from
each ﬁbrosis grade category was done using computer-generated
random numbers. Other laboratory investigations were conducted
to rule out etiologies of known liver pathology (e.g., hepatitis B and
alcoholism). Blood (10 ml) was collected from each subject
enrolled. Serum was separated from the whole blood and
refrigerated at 2–8 8C. Collected sera were then transferred to a
4 8C cooler box and shipped to the Research Institute for Tropical
Medicine (RITM) clinical laboratory in Manila. Each serum sample
was divided into equal aliquots. Half of the serum specimens were
used for liver function and hepatitis B surface antigen (HBsAg)
testing and the other half was kept at 80 8C for use in ﬁbrosis
marker assays. Hepatitis C testing was excluded due to the very
low prevalence (<3%) reported for rural remote communities in
the Philippines. Liver function (including tests for hepatocellular
injury, parenchymal damage, capacity for protein synthesis, and
cholestasis) and HBsAg tests were performed on the samples using
an automated machine (A15; Biosystems S.A., Barcelona, Spain)
and commercial enzyme immunoassay kits (MONOLISA; Bio-Rad[29_TD$DIFF],
Marnes-la-Coquette, France), respectively. The serum samples for
ﬁbrosis marker testing were transferred to Siemens, Australia who
evaluated HA, procollagen type III (PIIINP), and tissue inhibitor of
metalloproteinase 1 (TIMP-1) serum levels using the ELF test.21
The ADVIA Centaur CP XP Immunochemical [31_TD$DIFF]Analyzer Bayswater,
( [32_TD$DIFF]Victoria, Australia) was used according to the manufacturer’s
instructions. The ELF score was calculated directly by the
instrument using the following equation:
ELF score ¼ 2:278þ 0:851 lnðCHAÞ þ 0:751 lnðCP3NPÞ
þ 0:394 lnðCTIMP1Þ
The serum levels of soluble intercellular adhesion molecule 1
(sICAM-1) were measured at QIMR Berghofer Medical Research
Institute using a separate ELISA kit (R&D systems, Minneapolis,
MN, USA).
2.3. Study oversight
Ethical consent for the study was obtained from the ethics
review boards of the Department of Health in the Philippines
(Institutional Review Board Number 2012-13-0), Grifﬁth Univer-
sity, Australia, and QIMR Berghofer Medical Research Institute,
Australia. Written informed consent was obtained from each
individual or from the parents/legal guardians of those aged <15
years. Stool-positive subjects were treated orally with 60 mg/kg
PZQ in two divided doses, followed by another treatment of the
same dose 2 weeks later. Stool-negative individuals were treated
with a single oral dose of 40 mg/kg.
2.4. Statistical analysis
FoxPro version 6.0 ( [33_TD$DIFF]Microsoft Corp) was used for double-entry
of data. Data were cross-checked and analyzed using SAS version
9.4 (SAS Institute, Cary, NC, USA). The statistical analysis was
performed using Stata version 11 (StataCorp LP, College Station, TX,
USA). Data were summarized as frequencies or the mean 
standard deviation, as appropriate. All categorical variables were
evaluated using the Chi-square test. Wilcoxon signed-rank andMcNemar tests were used for paired analysis of infection intensity
and prevalence, respectively, across different age groups. With
regards to the impact of treatment on infection intensity, the S.
japonicum egg count + 1 was log10-transformed to bring observed
distributions closer to normality. The Kruskal–Wallis test was used to
detect signiﬁcant differences in the level of serum marker types
across ﬁbrosis grades. Receiver operating characteristics (ROC)
analysis was performed to assess the clinical utility of the three
serum ﬁbrosis markers (HA, TIMP-1, and PIIINP), both individually
and as their combined quantitative result (ELF score), in identifying
subjects with high-grade liver ﬁbrosis (grade II–III). A signiﬁcance
level of 5% was used for statistical inference.
3. Results
3.1. Study descriptors
Fifty-three percent of the study sample (n = 565) was male; the
mean age of the study subjects was 39.4 years (95% conﬁdence
interval (CI) 38–41 years). Most were poor rice farmers with a high
degree of exposure. There was no statistical difference in the sex
proﬁle of the sample. However, most of the study participants
belonged to age groups 36–45 years (24%) and 46–55 years (27%).
Only 1.0% of the population reported having been diagnosed with
hepatitis B; however, 38.4% drank alcohol moderately (consumed
1–2 drinks per day).
3.2. Prevalence, intensity, and morbidity outcomes
The study communities have participated in an active
schistosomiasis program for the past 20 years. However, the
prevalence of S. japonicum infection among the pre-treatment
cohort subjects (n = 565) was 34% (Figure 2). Males had a higher
prevalence of infection (46%) than females (20%). S.
japonicum infection was more prevalent (49%) among subjects
less than 20 years of age. The mean intensity of infection was
123.1 epg (95% CI 78.9–167.3 epg) (Figure 2).
Twenty-ﬁve percent had light intensity infections, 6% had
moderate intensity infections, and 2% had heavy infections.
Hepatic parenchymal ﬁbrosis occurred in 50% of subjects, with
grade II ﬁbrosis in 19% and grade III in 6% (Table 1). The prevalence
of ﬁbrosis was 52.7% (298/565) in males and 47.3% (267/565) in
females. The degree of liver ﬁbrosis correlated signiﬁcantly
(p = 0.0002) with the intensity of infection. The left and right
hepatic lobe lengths increased with increasing ﬁbrosis grade. The
mean left lobe lengths of those with grade II (mean length
93.7 mm, 95% CI 92.5–94.8 mm) and III (mean length 98.4 mm,
95% CI 96.4–100.4 mm) ﬁbrosis were signiﬁcantly longer
(p = 0.0001) than the lengths of those without ﬁbrosis (mean
length 87.7 mm, 95% CI 86.4–88.9 mm). However, only the mean
length of the right lobe of individuals with grade III ﬁbrosis
(122.3 mm, 95% CI 120.7–124.0 mm) was signiﬁcantly (p = 0.04)
longer compared with those lacking ﬁbrosis. Likewise, the mean
length of the spleen increased with increasing degree of ﬁbrosis,
although not signiﬁcantly (p = 0.21).
Four hundred and seventy-three subjects had both baseline and
follow-up stool examination results; these individuals were
utilized in the ﬁnal analysis to determine the impact of PZQ
treatment on the prevalence and intensity of infection. The
prevalence dropped signiﬁcantly 2 years post-treatment, especial-
ly among those aged 16–25 years (p = 0.008) and 46–55 years
(p = 0.001) (Figure 2). Similarly, the intensity of infection across all
age groups dropped compared with pre-treatment levels
(Figure 2). The prevalence decline observed among the 16–25
years age groupmay be due in part to limited exposure to infection.
On the other hand, acquired immunity to re-infectionmay partially
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Figure 2. Prevalence and intensity of infection in subjects with Schistosoma japonicum by age before (2012) and after (2015) 2 years of praziquantel treatment (i.e., 40–60 mg/
kg; n = 473).
Table 1
Dynamics of schistosomiasis liver parenchyma grading before and after praziquantel treatment in a cohort of 424 subjects from Northern Samar, Philippines, from 2012 to
2015
Parenchyma grading 2015 Total (n) Total (%) Progressed (%) Regressed (%)
Parenchyma grading 2012 Normal Grade [6_TD$DIFF] Grade [7_TD$DIFF] I Grade [8_TD$DIFF] II
Normal 156 54 3 0 213 50.24 26.8 0.0
Grade [6_TD$DIFF] 40 40 17 7 104 24.53 23.1 38.5
Grade [7_TD$DIFF] I 8 17 33 22 80 18.87 27.5 31.3
Grade [8_TD$DIFF] II 2 1 14 10 27 6.37 0.0 63.0
Total (n) 206 112 67 39 424 100 103 82
Table 2
Area under the receiver operating characteristics curve (AUC) and diagnostic
sensitivities and speciﬁcities for ELF score cut-off values and individual serum
markers of ﬁbrosis at baseline and 2 years after treatment to distinguish between
severe ﬁbrosis (grade II–III) and mild ﬁbrosis (grade 0–I)
Fibrosis marker AUC p-Value Sensitivity Speciﬁcity Cut-off
Baseline (n = 177)
ELF 0.68 <0.001 64 71 9.2
Hyaluronic acid 0.69 <0.001 66 72 30.7
PIIINP 0.56 0.515 61 51 10.2
TIMP-1 0.65 <0.001 63 68 253.6
Follow-up (n=180)
ELF 0.62 0.004 62 62 8.9
Hyaluronic acid 0.63 0.043 73 53 26.3
PIIINP 0.57 0.475 58 57 9.4
TIMP-1 0.62 0.001 73 51 183.7
ELF, enhanced liver ﬁbrosis test; PIIINP, procollagen type III; TIMP-1, tissue inhibitor
of metalloproteinase 1.
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However, only subjects aged 46–55 years showed signiﬁcant
decreases in the intensity of infection compared with the baseline
ﬁndings (p = 0.003). The prevalence of grade II–III ﬁbrosis
remained relatively unchanged at 25.2% (107/424) on follow-up
(Table 1). The data suggest that a 2-year follow-up period may be
too short a time frame to assess disease regression following
treatment.
3.3. Liver function tests, hepatitis B, and serum ﬁbrosis markers
Liver function tests were performed on a selected subset of
patients (n = 136). The total number of individuals was derived via
age-matched speciﬁc grouping, resulting in 34 subjects for each of
the four ﬁbrosis clinical grades. Sixty percent (81/136) of the
subjects had normal liver function tests, with the proportion being
uniform across all ﬁbrosis grades. Mild alanine aminotransferase
elevation was noted in 1.5% (2/136) of the sample. Alkaline
phosphatase and total bilirubin results were similarly distributed
among the four ﬁbrosis groups.
HBsAg testing was done on all 565 subjects. The HBsAg carrier
rate was 4.2% (24/565). The carrier rates in those with grades I, II,
and III ﬁbrosis were 1.4% (2/145), 2.8% (3/105), and 2.9% (1/34),
respectively. The carrier rates in those with ﬁbrosis were actually
lower than the rates in those without ﬁbrosis (6.4%). Thus, the
prevalence of both alcohol and chronic hepatitis B-induced liver
ﬁbrosis were demonstrated to be low in the cohort.
The serum ﬁbrosis marker levels and infection intensity before
and after PZQ treatment were also assessed. Only baseline mean
TIMP-1 levels showed cumulative results with increasing intensity
of infection (p = 0.001). The baseline and endpoint serum levels of
the ﬁbrotic markers were also compared with parenchymalgrading. The ELF marker score and two of three ELF markers
correlated with the severity of ﬁbrosis. The mean baseline and
follow-up ELF scores correlated signiﬁcantly with increasing liver
ﬁbrosis grade (p = 0.002, p = 0.049). Before treatment, baseline
TIMP-1 levels were increased in all three increasing ﬁbrosis grades
(p < 0.001). At the endpoint, TIMP-1 levels were also signiﬁcantly
higher in grade III compared with grade I (p = 0.034). The HA levels
were higher in grade III compared with grade 0 (p = 0.031) and
grade I (p = 0.0429). sICAM-1 was also correlated with the grade of
ﬁbrosis (p = 0.0013).
Table 3
Mean ﬁbrosis marker value by intensity of infection and ﬁbrosis grade
Intensity of infection n ELF HA PIIINP TIMP-1
Grade 0
Negative 68 8.8 31.6 12.1 199.8
Mild 10 8.9 23 14.7 252.5
Moderate 2 8.5 21.4 8.2 278.1
Heavy 0
Grade 1
Negative 0
Mild 7 8.8 23.2 13.7 295.3
Moderate 4 9 27.3 13.6 290.1
Heavy 1 9.4 12 27.6 594.5
Grade 2
Negative 14 9.3 41.1 12.3 294.6
Mild 17 9.1 46.5 10.3 274.6
Moderate 4 9.4 59.2 10 241.1
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Table 2 shows the baseline and follow-up ROC curve analysis
results of the ELF score and individual markers to differentiate
subjects with grade II–III ﬁbrosis (severe) from thosewith grade 0–
I ﬁbrosis (mild). The diagnostic accuracies of HA and the ELF score
were slightly higher than those of the other two ELF markers
assessed based on the area under the curve (AUC) at baseline. At
follow-up, HA, TIMP-1, and the ELF score had higher diagnostic
accuracy than PIIINP. The cut-off value of 30.7 ng/ml for HA (AUC
0.69, p < 0.001) and 9.2 for the ELF score (AUC 0.68, p < 0.001) to
discriminate grade II–III ﬁbrosis fromgrade0–I among177 subjects
at baseline showed sensitivities of 66% and 64%, respectively, and
speciﬁcities of 72% and 71%, respectively. At follow-up, the cut-off
value of 26.3 ng/ml for HA (AUC 0.63, p < 0.043), 183.7 ng/ml forHeavy 1 7.7 5.6 10.5 277.1
Grade 3
Negative 8 10 85.5 21.4 302.8
Mild 10 9.6 64.6 11.2 279.5
Moderate 3 10.2 76.2 14.2 370.4
Heavy 2 8.7 24.1 10.3 457.8
ELF, enhanced liver ﬁbrosis test; HA, hyaluronic acid; PIIINP, procollagen type III;
TIMP-1, tissue inhibitor of metalloproteinase 1.
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Figure 3. Baseline ROC curves (n = 177) for the enhanced liver ﬁbrosis (ELF) score
and serum concentrations of hyaluronic acid (HA), procollagen type III (PIIINP), and
tissue inhibitor of metalloproteinase 1 (TIMP-1) for differentiating grade II–III liver
ﬁbrosis from grade 0–I ﬁbrosis..
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Figure 4. Follow-up ROC curves at 2 years post-treatment (n = 180) for the
enhanced liver ﬁbrosis (ELF) score and serum concentrations of hyaluronic acid
(HA), procollagen type III (PIIINP), and tissue inhibitor of metalloproteinase
1 (TIMP-1) for differentiating grade II–III liver ﬁbrosis from grade 0–I ﬁbrosis.TIMP-1 (AUC 0.62, p < 0.001), and 8.9 for the ELF score (AUC 0.62,
p < 0.004) to discern grade II–III ﬁbrosis from grade 0–I among
180 subjects showed sensitivities of 73%, 73%, and 62%, respec-
tively, and speciﬁcities of 53%, 51%, and 62%, respectively. PIIINP
was uninformative, having the lowest AUC for both time points.
Figures 3 and 4 illustrate the ROC curves for the three individual
ELF markers and the curves for the ELF score. The ELF score and HA
showed the highest diagnostic performance in detecting severe
schistosome-induced liver ﬁbrosis. When sex was considered, no
signiﬁcant differencewas observed in the cut-off values at baseline
and at 2 years of follow-up. Cut-off values of 8.9 ng/ml and 9.2 ng/
ml were noted for males (baseline: AUC 0.69, p = 0.003; follow-up:
AUC 0.62, p = 0.342) and females (baseline: AUC 0.64, p = 0.226;
follow-up: AUC 0.69, p = 0.042), respectively, suggesting that the
same cut-off value can be utilized for both sexes. However, when
age was taken into account, the cut-off value at baseline was noted
to be higher among subjects younger than 18 years of age (9.9 ng/
ml, AUC 0.96, p = 0.192) compared with those aged 18–40 years
(8.9 ng/ml, AUC 0.71, p = 0.087), 41–50 years (8.9 ng/ml, AUC 0.74,
p = 0.005), and over 50 years (9.2 ng/ml, AUC 0.61, p = 0.046). This
suggests that age may inﬂuence the ELF test results. On follow-up,
the cut-off values could not be determined for the adolescent (<18
years) cohort because very few of these individuals had moderate
to severe ﬁbrosis.
Overall, the mean values of the ﬁbrosis markers seemed to
increase across the ﬁbrosis grades, except for PIIINP (Table 3).
However, within each grade, there seemed to be no apparent
pattern across intensity of infection. This observation may be due
to the small sample size within each category.
4. Discussion
In this study, the prevalence of schistosomiasis, level of
infection intensity, and level of morbidity was evaluated among
565 subjects residing in 18 moderately endemic barangays in
Northern Samar, the Philippines. The study communities have
participated in the National Department of Health human
treatment program for schistosomiasis over the past three
decades. Nevertheless, the baseline human prevalence and
infection intensity were 34% and 123 epg, respectively. Baseline
ultrasonography revealed a high level of schistosomiasis-induced
morbidity among subjects with signs and symptoms suggestive of
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Figure 5. Algorithm for the recommended diagnosis and management of severe
hepatic ﬁbrosis (grade II–III) due to gastrointestinal schistosomiasis infection.
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liver enlargement (70 mm) and 25% had grade II or III liver
ﬁbrosis. Splenomegaly (100 mm) was seen in 13% of the
population. Infection intensity was signiﬁcantly correlated with
grade III ﬁbrosis (p < 0.0002). Hepatitis B virus, alcoholism, and
malaria were excluded as possible causes. The results suggest that
the national control strategy for schistosomiasis (i.e., human
treatmentwith 40 mg/kg PZQ) is inadequate in the study area. Low
drug coverage (<36%), low drug compliance (<40%), and the
inability of PZQ to prevent re-infection given the zoonotic nature of
the disease may have contributed to the ﬁndings.22 [30_TD$DIFF]
As expected, a reduction in both the prevalence and intensity of
infectionwere noted at 2 years after chemotherapy (i.e., 40–60 mg/
kg PZQ) compared to baseline. However, treatment had less of an
impact on lowering schistosomiasis-induced morbidity. Overall,
hepatic ﬁbrosis (grades I–III) regressed in only 24.3% of those who
received a single treatment and in only 19.3% of those who
received two PZQ doses. This outcome is similar to that reported
for S. japonicum morbidity in China.9 The baseline prevalence of
grade II–III ﬁbrosis was 25.2%, but this remained unchanged at
2 years post-treatment. Individuals with signiﬁcant morbidity
despite standard treatment will need a longer treatment course at
a higher dose (i.e., 60–80 mg/kg) to reverse ﬁbrosis and improve
clinical outcomes. Approximately 10% of residents in Schistosoma
mansoni and S. japonicum endemic areas develop severe hepatos-
plenic disease.23–25 These observations have been explained in part
by genetic factors regulating disease development.23–25Liver
ﬁbrosis is a complex process involving the production and
deposition of insoluble components that comprise the extracellu-
lar matrix (ECM).9 Quantitative and qualitative ECM changes in
liver ﬁbrosis can be measured in blood or urine using indirect and
direct biomarkers.5 These biomarkers of hepatic matrix metabo-
lism have also been drawn together intomulti-parameter scores to
produce promising results.21,26 The ELF test is an ECM marker set
comprising an algorithm of three direct liver ﬁbrosis markers (HA,
TIMP-1, and PIIINP). The ELF test was one of the ﬁrst commercially
available serum ﬁbrosis tests,21 and its diagnostic potential has
been explored in identifying and staging liver ﬁbrosis among
patients with hepatitis C virus infection,21,27 alcoholic liver
disease,26 and non-alcoholic fatty liver disease (NAFLD).28 The
test is said to be comparable to FibroScan (transient elastogra-
phy)29,30 and more accurate or more reproducible than simple
panels (such as aspartate aminotransferase to platelet ratio and
Fibrosis-4) in detecting advanced ﬁbrosis.31,32 [34_TD$DIFF]
The present study assessed four promising direct biomarkers
(HA, PIIINP, TIMP-1, and sICAM-1) based on their performance in
previous studies.5,9,14,15 To the best of the authors’ knowledge, this
is the ﬁrst time that the ELF score has been deployed in the
evaluation of liver ﬁbrosis due to schistosomiasis. The best
correlation between serum marker level and ultrasonographic
ﬁbrosis grading was demonstrated with TIMP-1. TIMP-1 levels
increased as the degree of ﬁbrosis increased both at baseline and at
endpoint. The marker levels also decreased in all ﬁbrosis grade
categories at endpoint (after treatment), suggesting that serum
levels of TIMP-1 can be used to accurately assess liver ﬁbrotic
disease due to schistosomiasis. Also, TIMP-1 serum levels
correlated positively with the intensity of infection, suggesting
that the marker may also respond to inﬂammatory reactions to
eggs deposited in the liver. HA and sICAM-1 also showed some
correlation, but not as signiﬁcant as shown for TIMP-1. Moreover,
the ROC analysis revealed that HA as an individual marker showed
the highest sensitivity and speciﬁcity in discerning higher ﬁbrosis
grades from lower grades. The diagnostic performance of the ELF
score was equally as useful as that shown for HA alone. However,
the AUC values generated using both the ELF score and serum
biomarkers individually indicated only moderate discriminationbetween grades II–III and 0–I ﬁbrosis (i.e., AUC 0.6–0.7).33
Moreover, consistent with other studies, age should be considered
as a factor when generating ELF scores.21 An unadjusted ELF score
maymisclassify normal individuals younger than 18 years of age as
having moderate-to-severe schistosome-induced liver ﬁbrosis. If
the diagnostic value of the ELF test can be improved as a reliable
stand-alone test and suitable for ﬁeld application, then it could
potentially be deployed as a component of the diagnostic and
treatment algorithm for S. japonicum-infected patients (Figure 5).
In conclusion, a high level of schistosomiasis-induced morbidity
was demonstrated among subjects with signs and symptoms
suggestive of the disease in a moderately endemic area of the
Philippines that has been under active community-based chemo-
therapy for over three decades. Hepatic ﬁbrosis, the main cause of
hepatosplenic schistosomiasis, takes time to reverse with
chemotherapy. Individuals with hepatosplenic schistosomiasis
should be identiﬁed and treated as early as possible to prevent
disease progression and possible death. Serum ﬁbrosis
markers, particularly high TIMP-1 and HA levels, and ELF scores
above 8may potentially guide programmanagers on where to direct
limited health care resources for schistosomiasis control. More
speciﬁcally, if made affordable for ﬁeld application, the ELF test may
assist clinicians in assessing patients with heavy intensities of
infection (>400 epg) and/or with physical signs of advanced disease
(e.g., MCL >3) in determining their risk of severe liver ﬁbrosis[1_TD$DIFF].
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